Research programme: inflammatory disorders antibodies - Galapagos/MorphoSys

Drug Profile

Research programme: inflammatory disorders antibodies - Galapagos/MorphoSys

Latest Information Update: 26 Jul 2014

Price : $50

At a glance

  • Originator Galapagos NV; MorphoSys
  • Class Antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Osteoarthritis; Osteoporosis; Rheumatoid arthritis

Most Recent Events

  • 26 Jul 2014 Preclinical trials in Rheumatoid arthritis in Europe (Parenteral)
  • 26 Jul 2014 Preclinical trials in Osteoporosis in Europe (Parenteral)
  • 26 Jul 2014 Preclinical trials in Osteoarthritis in Europe (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top